Afinitor (everolimus) vs Vizimpro (dacomitinib)

Afinitor (everolimus) is a targeted therapy known as an mTOR inhibitor, commonly used in various types of cancer, including advanced renal cell carcinoma, certain breast cancers, and neuroendocrine tumors. Vizimpro (dacomitinib) is a type of targeted therapy known as an EGFR inhibitor, specifically designed for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. The choice between Afinitor and Vizimpro would depend on the type of cancer a patient has, the specific genetic mutations present in the cancer cells, and the overall treatment plan recommended by the healthcare provider.

Difference between Afinitor and Vizimpro

Metric	Afinitor (everolimus)	Vizimpro (dacomitinib)
Generic name	Everolimus	Dacomitinib
Indications	Advanced hormone receptor-positive, HER2-negative breast cancer, advanced neuroendocrine tumors, renal cell carcinoma, tuberous sclerosis complex-associated seizures, subependymal giant cell astrocytoma, and renal angiomyolipoma	First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations
Mechanism of action	mTOR inhibitor, which inhibits cell proliferation, angiogenesis, and glucose uptake	Tyrosine kinase inhibitor that irreversibly binds to and inhibits the activity of EGFR mutations
Brand names	Afinitor, Afinitor Disperz, Zortress	Vizimpro
Administrative route	Oral	Oral
Side effects	Stomatitis, infections, rash, fatigue, diarrhea, and decreased appetite	Diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus
Contraindications	Hypersensitivity to everolimus or other rapamycin derivatives	Hypersensitivity to dacomitinib or any component of the formulation
Drug class	mTOR inhibitor	EGFR tyrosine kinase inhibitor
Manufacturer	Novartis	Pfizer

Efficacy

Afinitor (Everolimus) Efficacy in Lung Cancer

Afinitor (everolimus) is an mTOR inhibitor primarily used to treat various types of cancers and tumors. Its efficacy in lung cancer, specifically non-small cell lung cancer (NSCLC), has been evaluated in several studies. Everolimus has been shown to have some effectiveness in treating NSCLC, particularly in patients who have progressed after treatment with other chemotherapeutic agents. It works by inhibiting the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, proliferation, and survival. By blocking mTOR, Afinitor can slow down the growth and spread of cancer cells.

While Afinitor is not primarily indicated for the first-line treatment of lung cancer, it may be considered in certain cases, such as when the cancer has a specific genetic profile or has not responded to other treatments. The drug's efficacy in lung cancer is enhanced when used in combination with other therapeutic agents, which can lead to improved outcomes in terms of progression-free survival. However, the overall survival benefit in lung cancer patients treated with Afinitor alone has been modest in clinical trials.

Vizimpro (Dacomitinib) Efficacy in Lung Cancer

Vizimpro (dacomitinib) is a pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Clinical trials have demonstrated that dacomitinib significantly improves progression-free survival compared to other EGFR inhibitors, such as gefitinib, in this patient population.

The efficacy of Vizimpro in treating lung cancer is particularly notable in patients with the aforementioned EGFR mutations. These mutations are more common in certain populations, such as non-smokers and those of Asian descent. In a pivotal phase III trial, dacomitinib showed a marked improvement in progression-free survival, which is a measure of the time during and after treatment that a patient lives with the disease without it getting worse. Moreover, Vizimpro has also been associated with a higher response rate compared to other EGFR inhibitors, suggesting that it can be an effective first-line treatment option for patients with EGFR-mutated NSCLC.

Regulatory Agency Approvals

Afinitor

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia

Vizimpro

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Afinitor or Vizimpro today

If Afinitor or Vizimpro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Afinitor

Buy Vizimpro

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: